Welcome to our dedicated page for ReWalk Robotics Ltd. news (Ticker: RWLK), a resource for investors and traders seeking the latest updates and insights on ReWalk Robotics Ltd. stock.
ReWalk Robotics Ltd. (formerly Argo Medical Technologies) is a pioneering company in the field of wearable robotic exoskeletons. Established in 2001, ReWalk aims to revolutionize the health and life experiences of individuals with spinal cord injury (SCI). Headquartered in the United States, Israel, and Germany, the company is committed to enhancing mobility and wellness for individuals with neurological conditions.
Core Business: ReWalk designs, develops, and markets innovative exoskeletons. The company's flagship product, the ReWalk exoskeleton, enables individuals with SCI to stand upright and walk by providing powered hip and knee motion. As the only exoskeleton with FDA clearance for personal use, ReWalk has been extensively tested in the U.S., Europe, and Israel, supported by the most published data in the rehabilitation market.
Recent Achievements: Recently, ReWalk supported the
ReWalk Robotics Ltd. (RWLK) reported a 36% increase in annual revenue for 2021, totaling $6.0 million, with Q4 revenues stable at $1.2 million. The company maintained a strong cash position of $88.3 million as of year-end. Despite progress in sales, gross margin decreased to 26% in Q4 2021 from 33% in Q4 2020, primarily due to inventory write-offs and increased service costs. Total operating expenses rose to $4.2 million in Q4, leading to a net loss of $3.9 million. The CEO noted significant advancements in coverage and technical developments for future growth.
ReWalk Robotics Ltd. (RWLK) will release its fourth quarter 2021 financial results on February 24, 2022, before U.S. markets open. CEO Larry Jasinski and CFO Ori Gon will lead a conference call at 8:30 A.M. EST to discuss these results. Investors can access the live and archived webcast via the company’s website. ReWalk develops wearable robotic exoskeletons aimed at improving the quality of life for individuals with lower limb disabilities. Founded in 2001, the company operates across the U.S., Israel, and Germany.
ReWalk Robotics Ltd. (Nasdaq: RWLK) announced the participation of CEO Larry Jasinski and CFO Ori Gon at the H.C. WAINWRIGHT BioConnect virtual conference from January 10-13, 2022. The fireside chat will be accessible on demand starting January 10 at 07:00 AM EST through a provided link. ReWalk Robotics focuses on developing wearable robotic exoskeletons for individuals with lower limb disabilities, aiming to enhance their quality of life. For more details, visit www.rewalk.com.
ReWalk Robotics Ltd. (Nasdaq: RWLK) has announced that CEO Larry Jasinski and CFO Ori Gon will present at the H.C. Wainwright 7th Annual Israel Virtual Conference on November 15, 2021, at 12:30 PM EST. The event will feature a company presentation and one-on-one meetings. The presentation will be accessible via a provided link and will also be available on the investor section of ReWalk's website. Founded in 2001, ReWalk develops wearable robotic exoskeletons aimed at improving the quality of life for individuals with lower limb disabilities.
ReWalk Robotics Ltd. (RWLK) reported a significant revenue increase in Q3 2021, totaling $2.0 million, up from $0.7 million in Q3 2020. The company's gross margin improved to 58% from 52% year-over-year. A major contributor to this growth was the sale of ReWalk Personal 6.0 units in Germany, alongside a large order from a U.S. physical therapy university. ReWalk also secured FDA breakthrough device designation for its ReBoot exoskeleton. The company holds a strong cash position with $91.2 million as of September 30, 2021.
ReWalk Robotics Ltd. (Nasdaq: RWLK) announced its third quarter 2021 earnings call set for November 11, 2021, at 8:30 AM ET. Investors can join via conference calls or a live webcast link. ReWalk specializes in wearable robotic exoskeletons designed to assist individuals with lower limb disabilities due to spinal cord injuries or strokes. The company aims to improve the quality of life through innovative robotic technologies, with operational headquarters in the U.S., Israel, and Germany.
ReWalk Robotics has announced that its ReBoot device has received Breakthrough Device designation from the FDA. This lightweight, battery-powered exo-suit is designed for stroke survivors with limited ankle function, aiding mobility at home and in the community. The designation facilitates a faster review process, aiming for timely market introduction. The ReBoot works with users' leg muscles to improve gait and prevent disuse atrophy, among other benefits. ReWalk plans to finalize the device's design and begin necessary clinical studies for FDA clearance.
ReWalk Robotics Ltd. (Nasdaq: RWLK) announced the closing of a registered direct offering of 16,013,518 ordinary shares at $2.035 per share, raising approximately $32.5 million, with unregistered warrants for an additional 8,006,759 shares issued concurrently. The funds will support sales, marketing, R&D for ReWalk's exoskeleton technologies, and general corporate purposes. H.C. Wainwright & Co. acted as the exclusive placement agent. The offering falls under a previously filed shelf registration with the SEC.
ReWalk Robotics Ltd. (Nasdaq: RWLK) announced a registered direct offering of 16,013,518 shares at $2.035 each, aiming to raise approximately $32.5 million. The funds will be allocated to market development for ReWalk devices, R&D for new technologies, routine product updates, and general corporate purposes. Concurrently, investors will receive warrants for an additional 8,006,759 shares at an exercise price of $2.00, with a term of five and a half years. The offering is expected to close on September 29, 2021, subject to customary conditions.
ReWalk Robotics Ltd. (RWLK) reported total revenue of $1.4 million for Q2 2021, marking the fourth consecutive quarter of growth. However, this figure is a decrease from $1.7 million in Q2 2020. The gross margin also fell to 51% from 61% year-over-year. Operating expenses increased to $3.9 million, resulting in a net loss of $3.1 million, slightly up from $2.9 million in the prior year. Despite these challenges, the company maintains a solid cash position of $64.2 million.
FAQ
What is the market cap of ReWalk Robotics Ltd. (RWLK)?
